| 1970 |
Optimal MSA for LM Crush Technique: New Criteria from AMC |
Do-Yoon Kang |
Nov. 02. 22 |
| 1969 |
Unmet Need for FFR in LM PCI |
Jung-Min Ahn |
Nov. 02. 22 |
| 1968 |
LM Revascularization 2022: Guidelines and Concept Change |
Duk-Woo Park |
Nov. 02. 22 |
| 1967 |
PCSK9 Inhibitor: Effect of Alirocumab on CV Events and Mortality After ACS |
Hanbit Park |
Apr. 08. 22 |
| 1966 |
Landscape of Lipid Management Following an ACS Event |
Choongki Kim |
Apr. 08. 22 |
| 1965 |
How is SAPIEN 3 Valve Design Connected to Clinical Benefit? |
Young-Guk Ko |
Apr. 08. 22 |
| 1964 |
Strategies of IVUS-Guided Left Main PCI with SYNERGY MEGATRON™ BP Stent |
Jeehoon Kang |
Apr. 08. 22 |
| 1963 |
SYNERGY MEGATRON – Advancing Your Large Proximal Vessel Strategy for Improved Outcomes |
Huay Cheem Tan |
Apr. 08. 22 |
| 1962 |
Comparison of 2 Different Paclitaxel-coated Balloons in Coronary In-stent Restenosis: A Randomized Controlled Trial |
Eun-Seok Shin |
Apr. 08. 22 |
| 1961 |
Influence of Baseline HbA1c and Antiplatelet Therapy on 1-year Vein Graft Outcome |
Qiang Zhao |
Apr. 08. 22 |
